Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.
Cell stem cell
MetadataShow full item record
Barker, R., Parmar, M., Studer, L., & Takahashi, J. (2017). Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.. Cell stem cell, 21 (5), 569-573. https://doi.org/10.1016/j.stem.2017.09.014
Stem cell based therapies for Parkinson’s disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.
Humans, Parkinson Disease, Stem Cell Transplantation, Adult, Aged, Middle Aged, Clinical Trials as Topic, Dopaminergic Neurons
We would like to thank Jeanne Loring and her team for contributing to the discussion and Table 1, Ulrika Blank Savukinas for illustration help, as well as all the funding agencies that have supported work within GForce-PD over the last few years including the EU (TRANSEURO and NeuroStemcellRepair no. 602278); the UK RMP Pluripotent stem cell hub; Cure Parkinson’s Trust; Rosetrees Trust; MRC-WT funding of the Cambridge Stem Cell Institute and the NIHR funding of the Biomedical Research Centre in Cambridge; The Swedish Research Council; The Swedish Brain foundation and the Swedish Parkinson Foundation; New York State Stem Cell Science (NYSTEM), and a grant from the Network Program for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development. MP is a New York Stem Cell Foundation Robertson Investigator.
EC FP7 CP (602278)
External DOI: https://doi.org/10.1016/j.stem.2017.09.014
This record's URL: https://www.repository.cam.ac.uk/handle/1810/275742
Attribution-NonCommercial-NoDerivatives 4.0 International
Licence URL: http://creativecommons.org/licenses/by-nc-nd/4.0/